Seborrheic dermatitis-like eruption following interleukin-2 administration.

Area of Science:

• Oncology
• Dermatology
• Immunology

Background:

• Recombinant interleukin-2 (rIL-2) is an immunotherapy used for certain cancers, including renal cell carcinoma.
• Adverse cutaneous reactions are known side effects of rIL-2 therapy.
• Seborrheic dermatitis-like eruptions have been anecdotally reported with rIL-2 but lack detailed histopathological data.

Observation:

• A 72-year-old male patient with metastatic renal cell carcinoma developed a facial scaly erythema after rIL-2 administration.
• Skin biopsy revealed intraepidermal and superficial perivascular mononuclear cell infiltrate.
• The infiltrate was predominantly composed of CD3-positive T-cells.

Findings:

• This case presents the first histopathological examination of a seborrheic dermatitis-like eruption induced by rIL-2.
• The findings support a T-cell mediated immune response in the pathogenesis of this specific adverse skin reaction.
• The histopathology shows similarities to other immune-related adverse events affecting the skin.

Implications:

• Understanding the histopathology of rIL-2-induced skin reactions can aid in diagnosis and management.
• This case highlights the importance of detailed histopathological evaluation for characterizing drug-induced dermatoses.
• Further research into immune-related adverse events is crucial for optimizing cancer immunotherapy protocols.